跳转至内容
Merck
CN

S8442

SU 5416

≥98% (HPLC), powder, neuronal nitric oxide synthase inhibitor

别名:

1,3-二氢-3-[(3,5-二甲基-1H-吡咯-2-基)亚甲基]-2H-吲哚-2-酮

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C15H14N2O
化学文摘社编号:
分子量:
238.28
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

SU 5416, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

color

yellow to yellow-orange

mp

221-222 °C

solubility

DMSO: 20 mg/mL, clear (warmed), H2O: insoluble

storage temp.

−20°C

SMILES string

Cc1cc(C)c(C=C2C(=O)Nc3ccccc23)[nH]1

InChI

1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8+

InChI key

WUWDLXZGHZSWQZ-XYOKQWHBSA-N

General description

SU 5416是一种血管内皮生长因子(VEGF)受体蛋白酪氨酸激酶1/2抑制剂。SU 5416可以抑制肿瘤生长和肿瘤血管新生。SU 5416抑制神经元型一氧化氮合酶活性,保护神经元细胞免遭一氧化氮介导的神经毒性伤害。也用作芳烃受体激动剂,还可能作为临床药物,有效治疗自身免疫疾病和移植排斥。

Application

SU 5416已用于在血管形成试验前处理人脐静脉内皮细胞(HUVEC),评估它对血管形成网络的影响。可诱发小鼠的肺动脉高压(PH)成为实验模型。

Biochem/physiol Actions

SU 516可抑制神经元一氧化氮合酶的活性并保护神经元细胞免受一氧化氮介导的神经毒性的影响。1 它还可作为芳烃受体的激动剂,是治疗自身免疫疾病和移植排斥的有效临床试剂。2
SU 5416是一种血管内皮生长因子(VEGF)受体蛋白酪氨酸激酶1/2抑制剂。

Features and Benefits

该化合物是激酶磷酸酶生物学研究的推荐产品。点击这里 发现更多精选激酶磷酸酶生物学产品。了解更多有关用于其他研究领域的生物活性小分子的信息,请访问 sigma.com/discover-bsm


存储类别

11 - Combustible Solids

ppe

dust mask type N95 (US), Eyeshields, Gloves



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


商品

Discover Bioactive Small Molecules for Kinase Phosphatase Biology


Cherine Abou Faycal et al.
Scientific reports, 9(1), 336-336 (2019-01-25)
The splice variant sVEGFR1-i13 is a truncated version of the cell membrane-spanning VEGFR1 receptor that is devoid of its transmembrane and tyrosine kinase domains. We recently showed the contribution of sVEGFR1-i13 to the progression and the response of squamous lung
Joshua D Mezrich et al.
PloS one, 7(9), e44547-e44547 (2012-09-13)
The experimental compound SU5416 went as far as Phase III clinical trials as an anticancer agent, putatively because of its activity as a VEGFR-2 inhibitor, but showed poor results. Here, we show that SU5416 is also an aryl hydrocarbon receptor
Loredana Ciuclan et al.
American journal of respiratory and critical care medicine, 184(10), 1171-1182 (2011-08-27)
The complex pathologies associated with severe pulmonary arterial hypertension (PAH) in humans have been a challenge to reproduce in mice due to the subtle phenotype displayed to PAH stimuli. Here we aim to develop a novel murine model of PAH



全球贸易项目编号

货号GTIN
S8442-25MG04061836960797
S8442-5MG04061836960803